Oslo Myeloma Center is the largest center for clinical myeloma research in the Nordics. The largest endeavor in 2019 was to move the entire group from Rikshospitalet to new facilities at building 20 in Ullevål hospital. Yet, we managed to enroll what was a group and national record of 128 patients for a cancer disease in a year, in studies within all phases of disease, from phase 1 to phase 4.
In 2019, 120 patients were enrolled in 14 clinical studies, in young and elderly, in newly diagnosed and in patients with one or multiple relapses, in phase, 1, 2, 3 and 4 studies.
Number of patients included in the different phases:
Phase 1 - 3 patients
Phase 2 - 49 patients
Phase 3 - 46 patients
Phase 4 - 22 patients
The biggest accomplishment during 2019 was to set up the first CAR-T-cell trial for myeloma in the Nordics, which continues to enroll in 2020. We were also able to fully finance the first completely, in many senses of the word, national study in myeloma, REMNANT; established through the newly founded Norwegian Myeloma Association, and discussed in the newly started Norwegian Myeloma Workshops, both entities initiatives from OMC.
We collaborate with basal and translational research groups, especially with the KG Jebsen center for B cell malignancies at our hospital, with projects in drug-sensitivity screening, pathophysiology and immune therapy. In addition, we have a myeloma registry with both prospective and retrospective data.